Zynex (NASDAQ:ZYXI) Releases Q1 2025 Earnings Guidance

Zynex (NASDAQ:ZYXI) issued an update on its first quarter 2025 earnings guidance on Tuesday morning. The company provided EPS guidance of -0.300- for the period, compared to the consensus EPS estimate of 0.060. The company issued revenue guidance of $30.0 million-, compared to the consensus revenue estimate of $53.5 million.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $17.00 price objective on shares of Zynex in a research note on Friday, December 6th.

Zynex Price Performance

NASDAQ ZYXI traded down $0.17 on Tuesday, hitting $7.00. The company had a trading volume of 119,612 shares, compared to its average volume of 111,921. The company has a debt-to-equity ratio of 1.66, a current ratio of 3.94 and a quick ratio of 3.15. The company has a market capitalization of $222.92 million, a PE ratio of 46.67 and a beta of 0.81. Zynex has a 12-month low of $5.44 and a 12-month high of $13.19. The company’s fifty day moving average price is $7.74 and its 200-day moving average price is $8.02.

Zynex (NASDAQ:ZYXI) last issued its quarterly earnings results on Tuesday, March 11th. The company reported ($0.02) EPS for the quarter, missing the consensus estimate of $0.09 by ($0.11). Zynex had a return on equity of 13.05% and a net margin of 2.49%. During the same period in the previous year, the firm earned $0.04 EPS. As a group, analysts predict that Zynex will post 0.2 earnings per share for the current year.

Insider Activity at Zynex

In other Zynex news, CFO Daniel J. Moorhead sold 10,000 shares of the company’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $7.68, for a total value of $76,800.00. Following the completion of the sale, the chief financial officer now directly owns 19,738 shares in the company, valued at $151,587.84. This represents a 33.63 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In the last quarter, insiders sold 30,000 shares of company stock valued at $227,100. Corporate insiders own 52.13% of the company’s stock.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.